DLA Piper LLP (US)

DLA Piper LLP (US) handles a range of high value disputes in the sector, helping clients defend their patents in cross-border litigation and also providing support in product liability and personal injury MDLs arising out of allegations of faulty products or drugs. Licensing and supply agreements also fall within the group’s purview, where the group acts for both suppliers and buyers of critical medical ingredients. Heading the team are Matthew Holian, a Boston-based litigator whose practice encompasses multi-jurisdictional product liability disputes, and New York’s Andrew Gilbert, who advises both public and private life sciences companies on M&As and securities law; February 2024 saw the arrival of FDA regulatory specialists Vernessa Pollard and Anisa Mohanty from McDermott Will & Emery LLP‘s Washington office, advising on pre-market strategy and post-market compliance. Loren Brown represents clients across the spectrum of litigation pertinent to life sciences clients, including patent and trade secret infringement claims, and securities class actions, and Lucas Przymusinski focusing on product liability suits tied to drugs and medical devices; both are located in New York. Boston’s Katie Insogna is recommended for her ability to handle both regulatory issues and litigation, including MDLs tied to product liability, and broader commercial litigation.